Gilead Sciences Inc. (GILD)
Gilead Sciences Statistics
Share Statistics
Gilead Sciences has 1.25B shares outstanding. The number of shares has increased by 0.04% in one year.
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | 0.04% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 82.21% |
| Shares Floating | 1.24B |
| Failed to Deliver (FTD) Shares | 80 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 25.17M, so 2.02% of the outstanding shares have been sold short.
| Short Interest | 25.17M |
| Short % of Shares Out | 2.02% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is 239.97 and the forward PE ratio is 12.41. Gilead Sciences 's PEG ratio is -2.62.
| PE Ratio | 239.97 |
| Forward PE | 12.41 |
| PS Ratio | 4.01 |
| Forward PS | 4.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 10.64 |
| PEG Ratio | -2.62 |
Enterprise Valuation
Gilead Sciences Inc. has an Enterprise Value (EV) of 120.00B.
| EV / Earnings | 250.01 |
| EV / Sales | 4.17 |
| EV / EBITDA | 72.2 |
| EV / EBIT | 72.2 |
| EV / FCF | 11.08 |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 1.7 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 2.42%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 2.42% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | 26.67K |
| Employee Count | 18.00K |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 211.00M |
| Effective Tax Rate | 0.31 |
Stock Price Statistics
The stock price has increased by 50.31% in the last 52 weeks. The beta is 0.2, so Gilead Sciences 's price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | 50.31% |
| 50-Day Moving Average | 94.49 |
| 200-Day Moving Average | 81.74 |
| Relative Strength Index (RSI) | 73.33 |
| Average Volume (20 Days) | 7.92M |
Income Statement
In the last 12 months, Gilead Sciences had revenue of 28.75B and earned 480.00M in profits. Earnings per share was 0.38.
| Revenue | 28.75B |
| Gross Profit | 78.20M |
| Operating Income | 1.66B |
| Net Income | 480.00M |
| EBITDA | 1.66B |
| EBIT | 1.66B |
| Earnings Per Share (EPS) | 0.38 |
Balance Sheet
The company has 6.08B in cash and 24.99B in debt, giving a net cash position of -18.90B.
| Cash & Cash Equivalents | 6.08B |
| Total Debt | 24.99B |
| Net Cash | -18.90B |
| Retained Earnings | 16.30B |
| Total Assets | 54.52B |
| Working Capital | 3.05B |
Cash Flow
In the last 12 months, operating cash flow was 10.83B and capital expenditures 0, giving a free cash flow of 10.83B.
| Operating Cash Flow | 10.83B |
| Capital Expenditures | 0 |
| Free Cash Flow | 10.83B |
| FCF Per Share | 8.68 |
Margins
Gross margin is 0.27%, with operating and profit margins of 5.78% and 1.67%.
| Gross Margin | 0.27% |
| Operating Margin | 5.78% |
| Pretax Margin | 2.4% |
| Profit Margin | 1.67% |
| EBITDA Margin | 5.78% |
| EBIT Margin | 5.78% |
| FCF Margin | 37.66% |
Dividends & Yields
GILD pays an annual dividend of $3.16, which amounts to a dividend yield of 2.94%.
| Dividend Per Share | $3.16 |
| Dividend Yield | 2.94% |
| Dividend Growth (YoY) | 5.33% |
| Payout Ratio | 68.55% |
| Earnings Yield | 0.35% |
| FCF Yield | 7.9% |
Analyst Forecast
The average price target for GILD is $100, which is -9.1% lower than the current price. The consensus rating is "Buy".
| Price Target | $100 |
| Price Target Difference | -9.1% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
Stock Splits
The last stock split was on Jan 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.93 |
| Piotroski F-Score | 8 |